Tempus AI, Inc. Class A Common Stock (TEM)

Official site

HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

$76.05

+5.62 (+7.98%)

Market Cap: $12.85B

Last updated: Nov 06, 2026 at 4:42 PM ET

Earnings

Performance (10Y)

Beat Rate

90%(9/10)

Avg Surprise

+28.40%

Streak

7 Q

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$0.17

Range$-0.02 - $0.37

15 analysts

Revenue Consensus

$461M

Range$445M - $466M

21 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$0.17	$-0.02 - $0.37	-	-	15	-	-
Sep 30, 2026Sep 26 Reported Nov 2, 2026Reported Nov 2	$-0.21	$-0.32	$-0.41 - $-0.24	+34.38%	Beat	14	1 0 30d	-90.9%
Jun 30, 2026Jun 26 Reported Jul 30, 2026Reported Jul 30	$-0.35	$-0.41	$-0.49 - $-0.34	+14.63%	Beat	12	5 7 30d	-59.1%
Mar 31, 2026Mar 26 Reported May 5, 2026Reported May 5	$-0.13	$-0.20	$-0.31 - $0.08	+35.00%	Beat	12	0 1 30d	+45.8%
Dec 31, 2025Dec 25 Reported Feb 24, 2026Reported Feb 24	$-0.04	N/A	-	+80.00%	Beat	11	1 0 30d	+77.8%
Sep 30, 2025Sep 25 Reported Nov 4, 2025Reported Nov 4	$-0.11	$-0.18	$-0.30 - $-0.08	+38.89%	Beat	8	5 0 30d	+56.0%
Jun 30, 2025Jun 25 Reported Aug 8, 2025Reported Aug 8	$-0.22	$-0.25	$-0.39 - $-0.19	+12.00%	Beat	7	0 6 30d	+65.1%
Mar 31, 2025Mar 25 Reported May 6, 2025Reported May 6	$-0.24	$-0.27	$-0.38 - $-0.20	+11.11%	Beat	7	0 2 30d	+75.5%
Dec 31, 2024Dec 24 Reported Feb 24, 2025Reported Feb 24	$-0.18	$-0.15	$-0.20 - $-0.06	-17.49%	Miss	6	1 1 30d	-
Sep 30, 2024Sep 24 Reported Nov 4, 2024Reported Nov 4	$-0.25	$-0.28	$-0.49 - $-0.25	+10.71%	Beat	7	No revisions (30d)	-
Jun 30, 2024Jun 24 Reported Aug 6, 2024Reported Aug 6	$-0.63	N/A	-	+64.80%	Beat	-	-	-
Mar 31, 2024Mar 24 Reported Jun 17, 2024Reported Jun 17	$-0.98	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-104.18	EV/EBITDA	N/A
Price/FCF	-100.80x	FCF Yield	-0.99%
Profitability
Profit Margin	-12.50%	Operating Margin	-13.80%
ROE	-37.60%	ROIC	-7.44%
Financial Health
Debt/Equity	2.70x	Interest Coverage	-2.44x
Current Ratio	2.61x	Quick Ratio	2.48x
Trading Statistics
Beta	3.61	Avg Volume	6.43M
52-Week High	$89.09	52-Week Low	$40.77

Technical Indicators Dashboard

Moving Averages

SMA 10$74.44

SMA 20$70.75

SMA 50$71.32

SMA 200$57.13

EMA 10$73.87

EMA 20$72.77

EMA 50$69.86

EMA 200$62.36

MACD

Line: 1.25Signal: 0.77Hist: 0.48

ADX

ADX: 16.7+DI: 23.7-DI: 23.2

Aroon & PSAR

Aroon Up8.0

Aroon Down56.0

PSAR$84.08

Bollinger Bands

Upper Band$80.41

Lower Band$61.09

%B Position2731%(Upper)

Band Width0.77

RSI (14-Day)

Neutral

54.5

Momentum Oscillators

Stoch %K54.5

Stoch %D60.5

Williams %R-36.7

ROC (10d)12.5%

Momentum8.44

CCI (20d)63.4

MFI (14d)66.8

Volatility Measures

ATR (14d)$6.60(8.7%)

StdDev (20d)4.83

Hist Vol84.6%(High)

Volume Flow

VWAP$74.37

OBV193.3M

AD Line-8.2M

CMF (20d)0.101

Volume Metrics

Avg Vol (20d)6.4M

Vol Ratio1.0x

VWMA (20d)$71.77

Pivot Points

R3$81.26

R2$76.95

R1$73.69

Pivot Point$69.38

S1$66.12

S2$61.81

S3$58.55

Advanced Oscillators

TSI5.78

Ultimate Osc49.6

KST21.87

Financial Data

Quarter	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Revenue	$411.54M	$382.49M	$348.12M	$367.21M	$334.21M	$314.63M	$255.74M	$200.68M	$180.93M	$165.97M	$145.82M	$147.72M
Cost of Revenue	$144.84M	$135.99M	$126.08M	$129.50M	$124.26M	$119.60M	$100.53M	$78.62M	$75.09M	$90.46M	$68.12M	$66.18M
Gross Profit	$266.70M	$246.50M	$222.04M	$237.71M	$209.94M	$195.04M	$155.20M	$122.06M	$105.84M	$75.51M	$77.70M	$81.55M

Operating Expenses	$323.56M	$322.41M	$306.75M	$299.13M	$270.94M	$256.81M	$223.89M	$172.76M	$159.46M	$609.00M	$130.97M	$133.84M
R&D	$91.71M	$96.57M	$94.16M	$90.62M	$83.05M	$76.10M	$69.27M	$61.48M	$58.03M	$145.93M	$51.41M	$48.74M
SG&A	$231.86M	$225.84M	$212.59M	$208.51M	$187.89M	$180.71M	$154.63M	$111.29M	$101.43M	$463.07M	$79.56M	$85.10M
Operating Income	$-56,864,000	$-75,913,000	$-84,711,000	$-61,413,000	$-60,996,000	$-61,774,000	$-68,689,000	$-50,700,000	$-53,616,000	$-533,492,000	$-53,274,000	$-52,295,000

Interest Income	$3.98M	$3.90M	$3.87M	$5.12M	$4.60M	$1.09M	$1.81M	$3.55M	$4.79M	$1.72M	$1.03M	$1.74M
Interest Expense	$6.70M	$21.93M	$14.34M	$15.29M	$27.43M	$21.58M	$18.00M	$13.36M	$13.76M	$13.29M	$13.24M	$13.62M
Income Before Tax	$-12,448,000	$8.81M	$-122,895,000	$-57,009,000	$-81,224,000	$-40,531,000	$-112,334,000	$-10,356,000	$-74,110,000	$-552,117,000	$-64,732,000	$-50,269,000
Income Tax Expense	$35,000	$309,000	$-62,000	$-5,992,000	$276,000	$212,000	$-46,180,000	$122,000	$38,000	$95,000	$11,000	$214,000

Net Income	$-14,851,000	$5.64M	$-125,919,000	$-54,166,000	$-79,982,000	$-42,843,000	$-68,037,000	$-13,014,000	$-75,840,000	$-552,212,000	$-64,743,000	$-50,483,000

EBITDA	$18.45M	$54.62M	$-84,711,000	$-18,378,000	$-29,848,000	$8.77M	$-75,074,000	$-5,704,000	$-54,014,000	$-529,697,000	$-41,652,000	$-28,105,000
EBIT	$-9,732,000	$26.84M	$-112,420,000	$-46,845,000	$-58,391,000	$-20,045,000	$-96,144,000	$-543,000	$-65,138,000	$-540,540,000	$-52,525,000	$-36,645,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about TEM

Government Contracts

Gov Obligations (TTM)

$29.14M

Gov Obligations / Revenue

2.0%

Obligations YoY

403.6%

Active Awards

New Awards (TTM)

Avg Remaining Term

26.1 mo

Top agency: Department of Veterans Affairs at 56.9% of trailing twelve month obligations across 2 agencies

Recent Awards

Award ID	Agency	Obligated	Start	End	Description
75N99225C00002	Department of Health and Human ServicesNational Institutes of Health	$12.55M	Sep 18, 2025	Sep 17, 2030	ADAPT CRO SUPPORT SERVICES SOLICITATION
36C24E26N0165	Department of Veterans AffairsDepartment of Veterans Affairs	$8.39M	Jul 1, 2026	Jun 30, 2027	TASSO+ ASSAY TESTING FOR MVP PROGRAM
36C10G26N0028	Department of Veterans AffairsDepartment of Veterans Affairs	$5.53M	Jan 28, 2026	Jan 27, 2027	MODIFICATION P9 TO CHANGE THE CONTRACTING OFFICER AND ADD VAAR CLAUSE 852.222-71 COMPLIANCE WITH EXECUTIVE ORDER 13899
36C24E26N0050	Department of Veterans AffairsDepartment of Veterans Affairs	$2.70M	Mar 2, 2026	Mar 1, 2027	TASSO+ SEQUENCING FOR MVP PROGRAM

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

News

Tempus AI Director David R. Epstein Executes Sale of 370 Shares at $74.29 Under Rule 10b5-1 Plan

Tempus AI Director David R. Epstein sold 370 shares of Class A Common Stock at $74.29 per share on November 2, 2026. This transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on August 27...

Kalkine Media•Nov 5, 2026 5:10 AM ET11/5/26•Somewhat-Bearish

Selling at $74.29 a share, Tempus AI (TEM) director Epstein retains 30,474 shares.

Tempus AI, Inc. director David R. Epstein sold 370 shares of Class A Common Stock on November 2, 2026, at a price of $74.29 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in August...

Stock Titan•Nov 4, 2026 4:12 PM ET11/4/26•Somewhat-Bearish

A 100,000-share grant at Tempus AI (TEM) vests in eight quarters starting January 15, 2027.

Tempus AI officer Ryan Fukushima received a grant of 100,000 restricted stock units (RSUs) on November 2, 2026, which will vest in eight equal quarterly installments beginning January 15...

Stock Titan•Nov 4, 2026 4:12 PM ET11/4/26•Neutral

Tempus AI (NASDAQ:TEM) Posts First Adjusted Profit as Oncology and Data Demand Accelerate

Tempus AI (NASDAQ:TEM) reported its first adjusted profit and record third-quarter revenue, driven by accelerated oncology testing growth and strong demand for its data and applications segment. The company also raised...

Kalkine Media•Nov 3, 2026 4:12 AM ET11/3/26•Bullish

Tempus AI Q3 revenue rises 23% to $411.5m

Tempus AI reported a 23% year-over-year increase in Q3 2026 revenue, reaching $411.5 million and surpassing analyst expectations. The company also reported adjusted EPS of $0.07 against an expected loss and raised its...

grafa.com•Nov 2, 2026 7:36 AM ET11/2/26•Bullish

TEM Valuation and Fair Value

P/E: -104.2x
P/FCF: -100.8x
P/B: 27.6x

See GNG's fair value

TEM Profitability: Margins, ROIC and FCF

Gross margin: 64.5%
Operating margin: -13.8%
Net margin: -12.5%
ROIC: -7.4%
ROE: -37.6%
FCF margin: -9.1%
FCF yield: -1.0%

TEM Competitors

Company	Ticker
Summit Therapeutics PLC	SMMT
Penumbra Inc	PEN
BrightSpring Health Services, Inc. Common Stock	BTSG
Dr. Reddy’s Laboratories Ltd ADR	RDY
Baxter International Inc	BAX
DaVita HealthCare Partners Inc	DVA
Smith & Nephew SNATS Inc	SNN
Fresenius Medical Care Corporation	FMS

Sector: Healthcare

TEM Analyst Ratings

Consensus: Buy
Analysts: 20
Strong Buy: 2
Buy: 8
Hold: 9
Sell: 1
Strong Sell: 0

TEM Bull Case vs Bear Case

Bull case

TEM beat EPS estimates in 87.5% of its last 8 reported quarters.
TEM grew quarterly revenue 23.1% year over year.

Bear case

TEM has a -12.5% net profit margin.
TEM has a debt-to-equity ratio of 2.7x.

TEM Earnings: Beat Rate and Next Report

Beat rate: 7 of 8 quarters (87.5%)
Average surprise: 26.1%
EPS estimate (fiscal period ending Dec 31, 2026): $0.17

TEM Earnings Date

TEM reports Feb 22, 2027. The date is estimated.

TEM Earnings Call

The latest TEM earnings call transcript on file is labeled 2026Q3.

Read the 2026Q3 transcript

TEM ETF Holders

GNG tracks 22 ETFs that hold TEM. The largest weights:

ARK Genomic Revolution ETF (ARKG), 8.26% of the fund
ARK Innovation ETF (ARKK), 5.47% of the fund
MarketDesk Focused U.S. Momentum ETF (FMTM), 2.59% of the fund
KraneShares Public-Private AI & Technology ETF (AGIX), 1.59% of the fund
ERShares Private-Public Crossover ETF (XOVR), 1.39% of the fund

Open the ETF Stock Exposure tool for TEM

Frequently Asked Questions About TEM

When does TEM report earnings?

Tempus AI, Inc. Class A Common Stock (TEM) is expected to report earnings on Feb 22, 2027.

Does TEM pay dividends?

Tempus AI, Inc. Class A Common Stock (TEM) does not currently pay a regular dividend.

What is TEM's market cap?

Tempus AI, Inc. Class A Common Stock (TEM) has a market capitalization of $12.85B with a current stock price of $76.05.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In